Severe allergic asthma treatment in Poland
Journal Title: JOURNAL OF HEALTH POLICY & OUTCOMES RESEARCH - Year 2016, Vol 10, Issue 2
Abstract
Severe asthma is a heterogeneous disease, which, as it is now believed, requires a personalized therapy dependent on phenotype. Omalizumab, a humanized monoclonal antibody that specifically binds to free immunoglobulin E, proved to be particularly effective in the treatment of allergic asthma. Because this treatment is very expensive, in Poland it is reimbursed under the drug program: “Omalizumab treatment of severe, allergic, IgE-dependent asthma”. One of the main features of drug programs is precise defining the group of patients, which may be subject to treatment. The current experience shows that it significantly increase the efficacy of the therapy. On the other hand, however, may adversely affect the possibility of treating patients with difficult access to specialized centres.
Authors and Affiliations
Aleksandra Kucharczyk, Joanna Mazurek, Karina Jahnz-Różyk
Keywords
Related Articles
- EP ID EP192274
- DOI 10.7365/JHPOR.2016.2.6
- Views 65
- Downloads 0
Severe allergic asthma treatment in Poland
Severe asthma is a heterogeneous disease, which, as it is now believed, requires a personalized therapy dependent on phenotype. Omalizumab, a humanized monoclonal antibody that specifically binds to free immunoglobulin E...
Multiple Criteria Decision Analysis (MCDA) for Health Care Decision Making – overview of guidelines
Multidimensional context of decision making in health care implies the need for structured approach which can be supported by Multiple Criteria Decision Analysis (MCDA). Despite the fact that MCDA is more widely discuss...
The access to an ophthalmic treatment in Poland on the example of the ocular complications in the course of diabetes mellitus
Background Diabetic Retinopathy (DR) is the severe disease, that develops as a result of diabetes complication. All diabetic patients are at risk of DR development and the National Health Fund (NHF) estimates that ther...
Cost-utility analysis and budget impact analysis of pegvisomant for the treatment of adult patients with acromegaly in Poland
Background: The aim of this publication was to evaluate the cost-effectiveness and financial consequences of pegvisomant (PEG) in the treatment of adult patients with acromegaly, who have had an inadequate response to su...
Assessment of thrombocytopenia symptoms using vignettes. Preliminary report on the development and implementation of a new instrument
Objective: Our aim was to create a vignette enabling the assessment of the impact of thrombocytopenia symptoms on patients’ quality of life. Methods: The vignettes which we created are focused on thrombocytopenia sym...